Verici Dx plans fresh funding round to boost US test rollout

Verici Dx PLC (VRCI) is initiating a new equity funding round to support the US commercial rollout of its Tutivia transplant diagnostic, targeting $3.2 million in revenues for 2025. The funding, which includes a placing and retail offer, aims to extend the company's cash runway following Medicare coverage approval for Tutivia in April, a decision expected to significantly expand customer reach. Verici Dx's cash balance stood at $1.04 million at the end of May, with sufficient capital to operate through at least the end of July.

Analysis

Verici Dx PLC is initiating a new equity funding round to support the U.S. commercial rollout of its flagship transplant diagnostic, Tutivia, following a significant Medicare coverage decision secured in April which expands potential customer reach and reimbursement. The company is targeting $3.2 million in Tutivia revenues for 2025, indicating its strategic focus on this product used for detecting acute organ rejection. The planned fundraising, which has received early support from institutional investors and will include a retail offer, is crucial for extending Verici Dx's cash runway beyond its current capacity, which, despite a recent $750,000 milestone payment from Thermo Fisher related to its Pre-Transplant Risk Assessment (PTRA) test, stood at $1.04 million at the end of May, sufficient to operate only through at least the end of July. This capital raise aims to fund the necessary commercial scaling to capitalize on the Medicare approval, though details on its size and terms are pending an update by the end of June.

Key Decisions for Investors

• Investors should carefully evaluate the forthcoming terms of the equity fundraising, particularly the extent of dilution and the sufficiency of capital raised to achieve the $3.2 million Tutivia revenue target for 2025.
• Monitor the company's ability to convert the Medicare coverage for Tutivia into tangible sales growth and market penetration in the U.S. transplant diagnostics sector.
• Consider the near-term financial risk posed by the limited cash runway against the long-term growth potential offered by Tutivia's commercialization and the recent positive regulatory development.